Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVD-003
- Development stage
- Preclinical
- Lead developer
- Evozyne
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
EVD-003 is an experimental engineered cytokine being developed by Evozyne for the treatment of Crohn's disease. It is part of a platform of engineered proteins designed to decouple beneficial anti-inflammatory signaling from detrimental pro-inflammatory effects. By optimizing the cytokine's interaction with its receptors through protein engineering, the therapy aims to provide a more targeted approach to managing immune-mediated inflammatory disorders with an improved safety profile. As of early 2024, EVD-003 is in the discovery stage of development, with Evozyne planning its first IND submission for the broader program in 2026.
Beyond the preview
Go deeper on EVD-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVD-003.